Simplify Logo

Full-Time

Senior Network and Security Engineer

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

201-500 employees

Develops precision genetic medicines using base editing

Hardware
Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Category
Cybersecurity
Network Administration
IT & Security
Required Skills
Microsoft Azure
Python
Computer Networking
AWS
Requirements
  • Degree or certifications in Information Technology and/or Cyber-Security preferred
  • 5+ years of experience working in network engineering, security engineering, or similar environments
  • Demonstrated experience with AWS and Azure architecture and engineering
  • Experience troubleshooting networking protocols, switches, routers, and firewalls
  • Experience with Python and/or Infrastructure as Code (IaC) a big plus
  • Working experience with information security disciplines such as vulnerability management, incident response, forensics, conditional access, and security event management
  • Must be a natural collaborator, communicate effectively, and be flexible to changing business conditions
Responsibilities
  • Deploy cloud infrastructure networking and services following established architecture philosophies and approaches using Infrastructure as Code (IaC)
  • Work with Beam IT Business Partners to gather technical requirements in support of projects
  • Work with Beam’s security partners to triage, investigate, and remediate security events
  • Document work instructions and data flow diagrams
  • Research new technologies and identify opportunities to innovate
  • Support physical infrastructure in Beam office locations (firewalls, switches, routers, WAPs)
  • Support existing physical server footprint
  • Support virtual data center architecture with key integration partners

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise modifications to the genetic code to potentially correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and future commercialization of their treatments. Unlike many competitors, Beam Therapeutics emphasizes collaboration with pharmaceutical companies and research institutions, which helps them secure funding and advance their projects. Their goal is to advance scientific research and deliver effective, long-lasting treatments for patients.

Company Stage

IPO

Total Funding

$689M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

1%

1 year growth

-8%

2 year growth

-7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Beam Therapeutics' innovative base editing technology has the potential to revolutionize the treatment of genetic disorders, offering hope for lifelong cures.
  • The company's strong pipeline, including early-stage studies for sickle cell disease, positions it well for future growth and breakthroughs.
  • Significant investments and partnerships, like the recent $250 million deal with Eli Lilly, enhance Beam's financial stability and research capabilities.

What critics are saying

  • The recent retirement of CFO Terry-Ann Burrell and the layoff of 20% of staff could lead to operational disruptions and affect company morale.
  • Beam's focus on early-stage studies means that its treatments are still years away from commercialization, posing a risk to short-term revenue generation.

What makes Beam Therapeutics unique

  • Beam Therapeutics leverages base editing technology, which allows for precise genetic modifications, setting it apart from traditional gene-editing methods like CRISPR.
  • The company's focus on developing lifelong cures for genetic disorders, rather than temporary treatments, distinguishes it in the biotechnology sector.
  • Beam's strategic partnerships and licensing agreements, such as the $250 million deal with Eli Lilly, provide significant financial backing and collaborative opportunities.